Clinico-pathologic features of lung cancer with EML4-ALK translocation

被引：4
|
作者：
Mitsudomi, T. [1 ]
Suda, K. [1 ]
Tomizawa, K. [1 ]
Yatabe, Y. [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.10598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10598
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
    Ali, Greta
    Chella, Antonio
    Lupi, Cristiana
    Proietti, Agnese
    Niccoli, Cristina
    Boldrini, Laura
    Davini, Federico
    Mussi, Alfredo
    Fontanini, Gabriella
    ONCOLOGY LETTERS, 2015, 9 (04) : 1537 - 1540
  • [22] Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer
    Garces, Aimie E.
    Al-Hayali, Mohammed
    Lee, Jong Bong
    Li, Jiaxin
    Gershkovich, Pavel
    Bradshaw, Tracey D.
    Stocks, Michael J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (03): : 316 - 321
  • [23] Hope without hype: EML4-ALK inhibition for treatment of lung cancer
    Govindan, Ramaswamy
    LANCET ONCOLOGY, 2011, 12 (11): : 983 - 984
  • [24] Discovery and clinical application of a novel oncogene, EML4-ALK, in lung cancer
    Mano, Hiroyuki
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : S214 - S214
  • [25] EML4-ALK: Update on ALK Inhibitors
    Bearz, Alessandra
    Bertoli, Elisa
    Stanzione, Brigida
    De Carlo, Elisa
    Del Conte, Alessandro
    Bortolot, Martina
    Torresan, Sara
    Berto, Eleonora
    Da Ros, Valentina
    Pelin, Giulia Maria
    Fassetta, Kelly
    Rossetto, Silvia
    Spina, Michele
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (01)
  • [26] Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer
    Shaw, A. T.
    Yeap, B.
    Costa, D. B.
    Solomon, B. J.
    Kwak, E. L.
    Nguyen, A. T.
    Bergethon, K.
    Engelman, J. A.
    Iafrate, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] CLINICAL AND BIOLOGICAL FEATURES ASSOCIATED WITH EML4-ALK FUSION GENE IN NON SMALL CELL LUNG CANCER
    Choi, C.
    Jang, S. H.
    Hwang, Y. I.
    Jung, J. H.
    Lee, Y. Y.
    Lee, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S44 - S44
  • [28] Atypical Lung Carcinoids with EML4-ALK Fusion and Responses to ALK Inhibitors
    Waliany, Sarah
    Hung, Yin P.
    Abu Rous, Fawzi
    Do, Andrew
    Peterson, Jennifer
    Meservey, Caitlin
    Digumarthy, Subba R.
    Gadgeel, Shirish M.
    Lin, Jessica J.
    Meadori, Catherine B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E33
  • [29] Optic Neuropathy and Blindness Associated With Crizotinib for Non-Small-Cell Lung Cancer With EML4-ALK Translocation
    Chun, Stephen G.
    Iyengar, Puneeth
    Gerber, David E.
    Hogan, Robert N.
    Timmerman, Robert D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) : E26 - E27
  • [30] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Bilgin, Burak
    Sendur, Mehmet Ali Nahit
    Yucel, Sebnem
    Hizal, Mutlu
    Guner, Gurkan
    Akyurek, Nalan
    Erol, Cihan
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    Kilickap, Sadettin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2637 - 2643
12345